The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding.
Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA, Caria F, Schwartz R, Presby RE, Yang JH, Samels S, Correa M, Lubec G, Salamone JD.
Rotolo RA, et al. Among authors: presby re.
Front Pharmacol. 2019 Jun 28;10:682. doi: 10.3389/fphar.2019.00682. eCollection 2019.
Front Pharmacol. 2019.
PMID: 31316379
Free PMC article.